key: cord-0886946-v4pkwd44
authors: Tauzin, Alexandra; Nayrac, Manon; Benlarbi, Mehdi; Gong, Shang Yu; Gasser, Romain; Beaudoin-Bussières, Guillaume; Brassard, Nathalie; Laumaea, Annemarie; Vézina, Dani; Prévost, Jérémie; Anand, Sai Priya; Bourassa, Catherine; Gendron-Lepage, Gabrielle; Medjahed, Halima; Goyette, Guillaume; Niessl, Julia; Tastet, Olivier; Gokool, Laurie; Morrisseau, Chantal; Arlotto, Pascale; Stamatatos, Leonidas; McGuire, Andrew T.; Larochelle, Catherine; Uchil, Pradeep; Lu, Maolin; Mothes, Walther; Serres, Gaston De; Moreira, Sandrine; Roger, Michel; Richard, Jonathan; Martel-Laferrière, Valérie; Duerr, Ralf; Tremblay, Cécile; Kaufmann, Daniel E.; Finzi, Andrés
title: A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses
date: 2021-03-18
journal: bioRxiv
DOI: 10.1101/2021.03.18.435972
sha: 29fee5a8a2ac32ba3c8328df4e0caabf4dce5bc4
doc_id: 886946
cord_uid: v4pkwd44

The standard dosing of the Pfizer/BioNTech BNT162b2 mRNA vaccine validated in clinical trials includes two doses administered three weeks apart. While the decision by some public health authorities to space the doses because of limiting supply has raised concerns about vaccine efficacy, data indicate that a single dose is up to 90% effective starting 14 days after its administration. We analyzed humoral and T cells responses three weeks after a single dose of this mRNA vaccine. Despite the proven efficacy of the vaccine at this time point, no neutralizing activity were elicited in SARS-CoV-2 naïve individuals. However, we detected strong anti-receptor binding domain (RBD) and Spike antibodies with Fc-mediated effector functions and cellular responses dominated by the CD4+ T cell component. A single dose of this mRNA vaccine to individuals previously infected by SARS-CoV-2 boosted all humoral and T cell responses measured, with strong correlations between T helper and antibody immunity. Neutralizing responses were increased in both potency and breadth, with distinctive capacity to neutralize emerging variant strains. Our results highlight the importance of vaccinating uninfected and previously-infected individuals and shed new light into the potential role of Fc-mediated effector functions and T cell responses in vaccine efficacy. They also provide support to spacing the doses of two-vaccine regimens to vaccinate a larger pool of the population in the context of vaccine scarcity against SARS-CoV-2.

In the group of individuals that were previously infected, despite a decline in the amount To evaluate if vaccine responses were limited to RBD or could be extended to antibodies 151 against the full Spike glycoprotein, we used a cell-based ELISA (CBE) assay to measure levels 152 of antibodies recognizing the native full-length S glycoprotein expressed at the cell surface 47 . In 153 SARS-CoV-2 naïve individuals, the pattern was similar to that observed for the anti-RBD specific 154 response, with a level of total Spike-specific immunoglobulins similar to that observed in 155 previously-infected individuals before vaccination ( Figure 1E were stained with plasma samples and incubated with secondary Abs recognizing all Ab isotypes. 176

As expected, none of the SARS-CoV-2 naïve plasma samples obtained before vaccination 177 (baseline) recognized the SARS-CoV-2 Spike (D614G) or any of its variants (Figure 2A-E) . 178

However, they were able to recognize Spikes from endemic human coronaviruses (HCoV-OC43, 179

We examined whether prior SARS-CoV-2 infection alters the CD4 + and CD8 + T cell 238 responses to vaccination. To measure SARS-CoV-2-Spike-specific T cells in the two cohorts of 239 naïve persons and individuals with prior infection, we utilized two complementary methodologies, 240

T cell receptor (TCR) dependent activation induced marker (AIM) assays and intracellular 241 cytokine staining (ICS). We performed the cytokine-independent AIM assays as previously 242 described 61 with some modifications. We stimulated PBMC for 15h with an overlapping peptide 243 pool spanning the Spike coding sequence and measured upregulation of the markers CD69, 244 CD40L, 4-1BB and OX-40 upon stimulation. We used an AND/OR Boolean combination gating 245 strategy to identify antigen-specific T cell responses ( Figure S3A After vaccination, we observed a significant increase in total Spike-specific AIM + CD4 + T 251 cell responses in both groups of participants ( Figure 4A ) with significantly stronger responses in 252 the prior infection group compared to the naïve group. We observed similar patterns with Spike-253 specific AIM + cTfh responses which significantly increased after vaccination in both groups ( Figure  254 4B) and stronger in the prior infection group compared to the naïve group. In contrast, there was 255 a significant gain in Spike-specific AIM + CD8 + T cell responses after vaccination only in the 256 previous infected group. At the post-vaccination time points, AIM + CD8 + T cell responses were 257 also significantly higher than in the naïve group ( Figure 4C ). However, the frequencies range of 258 these responses remains significantly lower than that of AIM + CD4 + T cell responses regardless 259 of the time point studied ( Figure S3C ). 260

To assess functionality and polarization of the SARS-CoV-2-Spike-specific T cell 262 responses, we measured by ICS the cytokines secreted by CD4 + and CD8 + T cells in response 263 to a 6h stimulation of PBMC with a Spike peptide pool. T cells were analyzed for expression of 264 CD40L, CD107a, interferon (IFN)-γ, Interleukin (IL)-2, IL-10, IL-17A and tumor necrosis factor 265 (TNF)-α. IL-17A expression was undetectable for most participants in both CD4 + and CD8 + T cell 266 subsets, and CD40L negligible in CD8 + T cells. These subsets were thus not pursued, whereas 267 all other functions were included in further analysis. We defined frequencies of cytokine + CD4 + 268 and CD8 + T cells as percentage of cells positive for one or more cytokines or functional markers 269 There were only trends for an increase in CD4 + and CD8 + T cell responses after this single dose 275 of vaccine in the naïve cohort. 276

To qualitatively assess Spike-specific T cells in naïve and prior infection groups for 277 polyfunctional responses after vaccination, we performed coexpression analysis using Boolean 278 gating and examined each combinations of function ( Figure 4F and G). In comparison to naïve 279 individuals, dominant Spike-specific CD4 + T subsets that were preferentially increased by 280 vaccination in prior infection included Spike-specific CD4 + T cells coexpressing CD40L, IFN-γ and 281 TNF-α alone or in combination with other functions (CD107a, IL-2). The frequency of Spike-282 specific CD8 + T cells expressing IFN-γ or CD107a alone or combined together was also increased 283 in prior infection compared to naïve participants. 284

These data show that while a single dose of mRNA vaccine could induce detectable Spike-286 specific CD4 + and CD8 + T cells in most individuals, including Spike-specific cTfh cells, 287 independently of prior SARS-CoV-2 infection status, immunization elicited more robust and 288 functionally skewed responses in participants with a history of SARS-CoV-2 infection, compared 289 to naïve people, with preferential expansion of specific functional subsets. Most protective antibody responses are dependent on CD4 + T cell help, which is critical 294 for B cell expansion, affinity maturation and isotype switching. Therefore, we assessed whether 295 pre-existing SARS-CoV-2-Spike-specific CD4 + T cells and cTfh responses were predictive of 296 higher antibody titers and antibody functions, as measured by neutralization capacity and ADCC 297 after vaccination, irrespective of prior infection status ( Figure 5A ). We observed different patterns 298 of correlations between AIM + CD4 + , AIM + cTfh and ICS + CD4 + T cell frequencies measured before 299 vaccination and vaccine-induced antibody responses ( Figure 5A ). We found that correlations 300 between the function-agnostic AIM + CD4 + T cell measurements and antibody responses were 301 generally stronger than between ICS + CD4 + T cell responses and serological measurements 302 ( Figure 5A ). Notably, the Ig subsets measured after vaccination in the plasma of each participant 303 showed significant positive correlations between pre-existing Spike-specific CD4 + T cell and cTfh 304 responses on the one hand, and anti-Spike IgA and IgG post-vaccination on the other hand 305 ( Figure 5C , D, F and G). In contrast, we observed no significant correlations between total Spike-306 specific CD4 + T cell responses and anti-Spike IgM levels ( Figure 5B ) and between Spike-specific 307 cTfh responses and anti-Spike IgM levels ( Figure 5E ). At the functional level, we observed 308 significant correlations between all the pre-vaccination AIM + Spike-specific memory CD4 + T cells 309 and cTfh with ADCC and neutralization capacity post-immunization ( Figure 5A ).

These results suggest that pre-existing CD4 + T cell responses are beneficial for the 311 generation of specific and effective humoral responses against SARS-CoV-2 after a single dose 312 of mRNA vaccine, independently of prior SARS-CoV-2 infection. To investigate whether pre-existing humoral responses before vaccination predict the levels of 330 induced/boosted responses upon vaccination, we performed a tandem correlation analysis 331 focusing on pairs of correlations between time points before versus after vaccination ( Figure S4 ). 332

In naïve individuals, as expected, the low and SARS-CoV-2 unspecific responses before 333 vaccination didn't predict responses induced by vaccination. In contrast, individuals with previous 334 SARS-CoV-2 infection harbor a much broader set of parameters pre-vaccination that predict 335 induced responses post vaccination in the studied data set. Of interest, these correlations differ from the few observed in naïve individuals. In previously-infected individuals, most prominent 337 patterns include the predictive value of binding, ADCC, and neutralization responses pre-338 vaccination for IgA responses in CBE assays and neutralization against viruses with the E484K 339

Spike escape mutation post vaccination. 340

The mRNA vaccines have demonstrated a >90% efficacy starting 14 days after a single dose but 343 the immune correlate of protection after a single dose remains unknown 7,9,43 . Here we measured 344 several serological and cellular SARS-CoV-2-specific responses in SARS-CoV-2 naïve or 345

previously-infected individuals. Surprisingly, despite the proven vaccine efficacy three weeks after 346 vaccination 43,53 we observed no neutralizing activity in plasma from SARS-CoV-2 naïve 347 vaccinated individuals. Neutralization is thought to play a central role in SARS-CoV-2 vaccine 348 efficacy 7,54,55 , however, recent observations suggest that they might not be predictive, on their 349 own, of protection 65 . Affinity maturation through germinal center selection can lead to more potent 350 neutralizing antibody responses. While kinetics may differ according to the antigen used and route 351 of administration, measurable neutralizing titers may take several weeks to develop in humans 352 and NHP after immunization 66 , and even after neutralization titers begin to decrease, the somatic 353 hypermutation (SHM) process can continue for months after acute SARS-CoV-2 infection 67 . Our 354 results suggest that while the neutralization potency of vaccine-elicited antibodies is being 355 developed, other antibody functions such as Fc-mediated effector functions could contribute to 356 vaccine efficacy early on. Accordingly, three weeks after a single dose we observed strong ADCC 357 but no neutralization activity ( Figure 3) . Strikingly, vaccination of previously-infected individuals 358 induced a very significant increase of pre-existing humoral immunity including ADCC and 359 neutralization. Neutralization potency was increased enabling neutralization of several variants 360 including the B.1.1.7 variant, Spikes with the E484K mutation and even the phylogenetically more 361

We also demonstrated that the patterns of vaccine-induced T cell responses have 364 analogies with those observed for antibody immunity. A single dose of BNT162b2 mRNA vaccine 365 is also capable of generating SARS-CoV-2-specific T cell immune responses in both groups of individuals with a dominant CD4 + T cell responses, suggesting efficacy of the priming 367 immunization in generating cellular immunity against SARS-CoV-2. However, we observed 368 differences in the magnitude and quality of these responses between participants with and without 369 prior infection. Individuals who had already encountered SARS-CoV-2 developed strong Spike-370 specific memory CD4 + and CD8 + T cells, consistent with secondary memory responses to a recall 371 antigen. In contrast, naïve individuals showed significantly weaker Spike-specific CD4 + T cell 372 responses and low to undetectable Spike-specific CD8 + T cell responses by AIM and ICS. Even 373 though pre-vaccination T-cell responses to SARS-CoV-2 Spike glycoprotein were minimal in 374 almost all naïve participants, it is still possible that the vaccine amplifies preexisting CD4 + cross-375 reactive T cell responses to endemic human coronaviruses. This suggests that a single dose of 376 mRNA vaccine may be sufficient to elicit robust protective T cell responses in previously infected 377 individuals, naïve persons will likely most benefit from repeat immunization. 378

Our results support the parallel use of both AIM and ICS assays for SARS-CoV-2 vaccine 380 immunomonitoring. While most clinical trials relied on the IFN-γ ELISPOT assay and/or ICS to 381 measure T cell responses, our data suggest the notion that BNT162b2 and some other SARS-382

CoV-2 vaccines in advanced clinical evaluation have demonstrated that vaccines for SARS-CoV-383 2 vaccines preferentially elicit Th1 responses may have to be reconsidered 68-71 . Indeed, these 384 assays are sensitive for detection of Th1 cytokines and cytotoxic responses, but largely miss other 385 important components of virus-specific cellular immunity. Consistent with this, we found that AIM 386 assays detected vaccine-induced CD4 + and CD8 + T cells in natural infection 34 . Still, ICS assays 387 were essential to reveal qualitative differences in cellular responses elicited after vaccination in 388 previously infected versus naïve participants. With more proinflammatory and antiviral CD4 + and 389 CD8 + T cell functional profiles in almost all previously-infected individuals, including IFN-γ, TNF- doses the easier it will be to maximize the protection globally given the limited vaccine supply 442 worldwide. 443

All work was conducted in accordance with the Declaration of Helsinki in terms of informed 446 consent and approval by an appropriate institutional board. Blood samples were obtained from 447 donors who consented to participate in this research project at CHUM (19.381). Plasma and 448

PBMCs were isolated by centrifugation and Ficoll gradient, and samples stored at -80°C and in 449 liquid nitrogen, respectively, until use. 450

Plasma from SARS-CoV-2 naïve and previously-infected donors were collected, heat-inactivated 453 for 1 hour at 56°C and stored at -80°C until ready to use in subsequent experiments. Plasma from 454 uninfected donors collected before the pandemic were used as negative controls and used to 455 calculate the seropositivity threshold in our ELISA, cell-based ELISA, ADCC and flow cytometry 456 assays (see below). The RBD-specific monoclonal antibody CR3022 was used as a positive 457 control in our ELISA, cell-based ELISA, and flow cytometry assays and was previously described 

The SARS-CoV-2 RBD ELISA assay used was previously described 44,45 . Briefly, recombinant 490 SARS-CoV-2 S RBD proteins (2.5 μg/ml), or bovine serum albumin (BSA) (2.5 μg/ml) as a 491 negative control, were prepared in PBS and were adsorbed to plates (MaxiSorp Nunc) overnight 492 at 4°C. Coated wells were subsequently blocked with blocking buffer (Tris-buffered saline [TBS] 493 containing 0.1% Tween20 and 2% BSA) for 1h at room temperature. Wells were then washed four times with washing buffer (Tris-buffered saline [TBS] containing 0.1% Tween20). CR3022 495 mAb (50ng/ml) or a 1/250 dilution of plasma from SARS-CoV-2-naïve or previously-infected 496 donors were prepared in a diluted solution of blocking buffer (0.1 % BSA) and incubated with the 497 RBD-coated wells for 90 minutes at room temperature. Plates were washed four times with 498 washing buffer followed by incubation with secondary Abs (diluted in a diluted solution of blocking 499 buffer (0.4% BSA)) for 1h at room temperature, followed by four washes. HRP enzyme activity 500 was determined after the addition of a 1:1 mix of Western Lightning oxidizing and luminol reagents 501 Overnight rested PBMCs were stained with another cellular marker (cell proliferation dye 543 eFluor450; Thermo Fisher Scientific) and used as effector cells. Stained target and effector cells 544

were mixed at a ratio of 1:10 in 96-well V-bottom plates. Plasma from SARS-CoV-2 naïve or 545 previously-infected individuals (1/500 dilution) or monoclonal antibody CR3022 (1 µg/mL) were added to the appropriate wells. The plates were subsequently centrifuged for 1 min at 300xg, and 547 incubated at 37°C, 5% CO2 for 5 hours before being fixed in a 2% PBS-formaldehyde solution. and SARS-CoV-2 prior infection individuals (n=16). Lines connect data from the same donor. dataset was tested for statistical normality and this information was used to apply the appropriate 624 (parametric or nonparametric) statistical test. Differences in responses for the same patient before 625 and after vaccination were performed using Wilcoxon matched pair tests. Differences in 626 responses between naïve and previously-infected individuals were measured by Mann-Whitney 627 tests. Differences in responses against the SARS-CoV-2 variants for the same patient were 628 measured by Friedman test. P values < 0.05 were considered significant; significance values are 629 indicated as * p < 0.05, * * p < 0.01, * * * p < 0.001, * * * * p < 0.0001. Line charts were created with 630 

+ + + + - + + + + - - - + + - - - - + + - + - + + + - - + - + - - - - - + - + - - - + - + + - - + - + + - + + - + - - + + - - + - - + - - + + + + - - + - + + - - - + - + - - - + + - + + - - - - + + + - - - + + + - + - + - + - - - + - + - + - + - - + - - + - - - + - - + - - - - - + + - - - - + + - + - - - + - - - - - - + - - - - - + + - - - - - + *

An interactive web-based dashboard to track COVID-19 in 757 real time

WHO Coronavirus (COVID-19) Dashboard

Warp Speed" Needs Mind Melds, Not 760 Warped Minds

SARS-CoV-2 vaccines in development

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike 763

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked 765 by a Clinically Proven Protease Inhibitor

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell 769 responses

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A Visualisation Platform to 958

Create Open Outputs

Chapter